What price a cure?
The number of hugely expensive drugs to treat rare diseases is increasing but can we afford them?
Martin Shkreli recently gained widespread opprobrium when his company raised the price of Daraprim, a 62-year-old old drug used to treat Aids patients, by 5,000 per cent to more than $750 a pill.
The pricing strategy by Shkreli’s Turing Pharmaceuticals infuriated the public. Suddenly, pharmaceutical pricing entered the presidential debate in the US.
Billionaire Donald Trump, the Republican presidential frontrunner, called Shkreli a “spoiled brat”, while Democratic frontrunner Hillary Clinton tweeted about it ...
